<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39390047</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts.</ArticleTitle><Pagination><StartPage>23713</StartPage><MedlinePgn>23713</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23713</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-74641-9</ELocationID><Abstract><AbstractText>The COVID-19 pandemic remains a significant global health threat, with uncertainties persisting regarding the factors determining whether individuals experience mild symptoms, severe conditions, or succumb to the disease. This study presents an NMR metabolomics-based approach, analysing 80 serum and urine samples from COVID-19 patients (34 intensive care patients and 46 hospitalized patients) and 32 from healthy controls. Our research identifies discriminant metabolites and clinical variables relevant to COVID-19 diagnosis and severity. These discriminant metabolites play a role in specific pathways, mainly "Phenylalanine, tyrosine and tryptophan biosynthesis", "Phenylalanine metabolism", "Glycerolipid metabolism" and "Arginine and proline metabolism". We propose a three-metabolite diagnostic panel-comprising isoleucine, TMAO, and glucose-that effectively discriminates COVID-19 patients from healthy individuals, achieving high efficiency. Furthermore, we found an optimal biomarker panel capable of efficiently classify disease severity considering both clinical characteristics (obesity/overweight, dyslipidemia, and lymphocyte count) together with metabolites content (ethanol, TMAO, tyrosine and betaine).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tristán</LastName><ForeName>Ana Isabel</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Physics, Research Centre CIAIMBITAL, University of Almería, Ctra. Sacramento, s/n, 04120, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiménez-Luna</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biosanitary Research Institute of Granada (ibs.GRANADA), 18014, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Embryology, University of Granada, 18071, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abreu</LastName><ForeName>Ana Cristina</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Physics, Research Centre CIAIMBITAL, University of Almería, Ctra. Sacramento, s/n, 04120, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrabal-Campos</LastName><ForeName>Francisco Manuel</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Engineering, CeiA3, University of Almería, Ctra. Sacramento, s/n, 04120, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmerón</LastName><ForeName>Ana Del Mar</ForeName><Initials>ADM</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Physics, Research Centre CIAIMBITAL, University of Almería, Ctra. Sacramento, s/n, 04120, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez</LastName><ForeName>Firma Isabel</ForeName><Initials>FI</Initials><AffiliationInfo><Affiliation>Torrecárdenas University Hospital, 04009, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maresca</LastName><ForeName>Manuel Ángel Rodríguez</ForeName><Initials>MÁR</Initials><AffiliationInfo><Affiliation>Torrecárdenas University Hospital, 04009, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García</LastName><ForeName>Antonio Bernardino</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Torrecárdenas University Hospital, 04009, Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melguizo</LastName><ForeName>Consolación</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biosanitary Research Institute of Granada (ibs.GRANADA), 18014, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Embryology, University of Granada, 18071, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prados</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biosanitary Research Institute of Granada (ibs.GRANADA), 18014, Granada, Spain. jcprados@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100, Granada, Spain. jcprados@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Embryology, University of Granada, 18071, Granada, Spain. jcprados@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Physics, Research Centre CIAIMBITAL, University of Almería, Ctra. Sacramento, s/n, 04120, Almería, Spain. ifernan@ual.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PID2021-126445OB-I00</GrantID><Agency>State Research Agency of the Spanish Ministry of Science and Innovation</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PDC2021-121248-I00, PLEC2021-007774 and CPP2022-009967</GrantID><Agency>Gobierno de España MCIN/AEI/10.13039/501100011033 and Unión Europea "Next Generation EU"/PRTR</Agency><Country /></Grant><Grant><GrantID>PREDOC_01024</GrantID><Agency>Junta de Andalucía</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">NMR</Keyword><Keyword MajorTopicYN="N">Serum</Keyword><Keyword MajorTopicYN="N">Urine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390047</ArticleId><ArticleId IdType="pmc">PMC11467386</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-74641-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-74641-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Junior, C. D. S., Pereira, G., Kelly da Silva Fidalgo, C. M., Valente, A. P. &amp; T. &amp; Saliva NMR-based metabolomics in the war against COVID-19. Anal. Chem. 92(5), 15688–15692 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33215503</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldometer [COVID Live - Coronavirus Statistics]. https://www.worldometers.info/coronavirus/.</Citation></Reference><Reference><Citation>Schmelter, F. et al. Metabolic and lipidomic markers differentiate COVID-19 from non-hospitalized and other intensive care patients. Front. Mol. Biosci. 8, 737039. 10.3389/fmolb.2021.737039 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686182</ArticleId><ArticleId IdType="pubmed">34938772</ArticleId></ArticleIdList></Reference><Reference><Citation>Meoni, G. et al. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab. PLoS Pathog. 17, e1009243. 10.1371/journal.ppat.1009243 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7877736</ArticleId><ArticleId IdType="pubmed">33524041</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdés, A. et al. Metabolomics study of COVID-19 patients in four different clinical stages. Sci. Rep.12, 1650. 10.1038/s41598-022-05667-0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803913</ArticleId><ArticleId IdType="pubmed">35102215</ArticleId></ArticleIdList></Reference><Reference><Citation>Markley, J. L. et al. The future of NMR-based metabolomics. Curr. Opin. Biotechnol. 43, 34–40 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305426</ArticleId><ArticleId IdType="pubmed">27580257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart, D. S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discovery. 15, 473–484 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26965202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignoli, A. et al. High-throughput metabolomics by 1D NMR. Angew Chem. Int. Ed. 58, 968–994 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391965</ArticleId><ArticleId IdType="pubmed">29999221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari, S. et al. Quantitative metabolomics of saliva using proton NMR spectroscopy in patients with Parkinson’s disease and healthy controls. Neurol. Sci. 41, 1201–1210 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31897951</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira, L. R. P. et al. Salivary metabolite fingerprint of type 1 diabetes in young children. J. Proteome Res. 15, 2491–2499 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27306956</ArticleId></ArticleIdList></Reference><Reference><Citation>French, C. D. et al. NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system. PLoS Neglected Trop. Dis. 12, e0007045. 10.1371/journal.pntd.0007045 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312347</ArticleId><ArticleId IdType="pubmed">30557317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bathe, O. F. et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol. Biomarkers Prev. 20, 140–147 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21098649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani, Z. et al. A metabolic study on colon cancer using 1H nuclear magnetic resonance spectroscopy. Biochem. Res. Int. 2014 (348712). 10.1155/2014/348712 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4150403</ArticleId><ArticleId IdType="pubmed">25202454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtowicz, W. et al. Serum and urine 1H NMR-based metabolomics in the diagnosis of selected thyroid diseases. Sci. Rep. 7, 9108. 10.1038/s41598-017-09203-3 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567318</ArticleId><ArticleId IdType="pubmed">28831094</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens, N. S. et al. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J. Crohns Colitis. 7, e42–e48. 10.1016/j.crohns.2012.04.019 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22626506</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, B. et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 182, 59–72.e15. 10.1016/j.cell.2020.05.032 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco, H. et al. The specific metabolome profiling of patients infected by SARS-CoV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci. Rep. 10, 16824. 10.1038/s41598-020-73966-5 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7544910</ArticleId><ArticleId IdType="pubmed">33033346</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, J. W. et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell. Metab. 32, 188–202. 10.1016/j.cmet.2020.06.016 (2020). e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311890</ArticleId><ArticleId IdType="pubmed">32610096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, D. et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl. Sci. Rev. 7, 1157–1168 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197563</ArticleId><ArticleId IdType="pubmed">34676128</ArticleId></ArticleIdList></Reference><Reference><Citation>Marhuenda-Egea, F. C. et al. A metabolic readout of the urine metabolome of COVID-19 patients. Metabolomics. 19, 7. 10.1007/s11306-023-01971-6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873393</ArticleId><ArticleId IdType="pubmed">36694097</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosolanka, R. et al. Changes in the urine metabolomic profile in patients recovering from severe COVID-19. Metabolites. 13, 364. 10.3390/metabo13030364 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10058594</ArticleId><ArticleId IdType="pubmed">36984804</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers, M. S. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 6, e144455. 10.1172/jci.insight.144455 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821609</ArticleId><ArticleId IdType="pubmed">33232303</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, I., Pranata, R., Lim, M. A., Oehadian, A. &amp; Alisjahbana, B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther. Adv. Respir Dis. 14, 1753466620937175. 10.1177/1753466620937175 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336828</ArticleId><ArticleId IdType="pubmed">32615866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu, C. &amp; Marfella, R. COVID-19 and its cardiovascular effects: risk factors, prevention and management. J. Clin. Med. 12, 4457. 10.3390/jcm12134457 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10342677</ArticleId><ArticleId IdType="pubmed">37445492</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino, F. et al. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. Eur. Heart J. 44, 4141–4156 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37448181</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, J., Broadhurst, D. I., Wilson, M. &amp; Wishart, D. S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 9, 280–299 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608878</ArticleId><ArticleId IdType="pubmed">23543913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahnavard, A., Mann, B., Giri, A., Chatterjee, R. &amp; Crandall, K. A. Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity. Sci. Rep. 12, 12204. 10.1038/s41598-022-16396-9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9288092</ArticleId><ArticleId IdType="pubmed">35842456</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan, S. et al. Metabolic perturbation associated with COVID-19 disease severity and SARS-CoV-2 replication. Mol. Cell. Proteom. 20, 100159. 10.1016/j.mcpro.2021.100159 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490130</ArticleId><ArticleId IdType="pubmed">34619366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, J. et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat. Metab. 3, 1466–1475 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8475461</ArticleId><ArticleId IdType="pubmed">34580494</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos, A. F., Póvoa, P., Paixão, P., Mendonça, A. &amp; Taborda-Barata, L. Changes in glycolytic pathway in SARS-CoV-2 infection and their importance in understanding the severity of COVID-19. Front. Chem. 9, 685196. 10.3389/fchem.2021.685196 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461303</ArticleId><ArticleId IdType="pubmed">34568275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzzone, C. et al. SARS-CoV-2 infection dysregulates the metabolomic and lipidomic profiles of serum. iScience. 23, 101645. 10.1016/j.isci.2020.101645 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534591</ArticleId><ArticleId IdType="pubmed">33043283</ArticleId></ArticleIdList></Reference><Reference><Citation>Luporini, R. L. et al. Phenylalanine and COVID-19: tracking disease severity markers. Int. Immunopharmacol. 101, 108313. 10.1016/j.intimp.2021.108313 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8559801</ArticleId><ArticleId IdType="pubmed">34741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranovicova, E. et al. The ability to normalise energy metabolism in advanced COVID-19 disease seems to be one of the key factors determining the disease progression—A metabolomic NMR study on blood plasma. Appl. Sci. 11, 4231. 10.3390/app11094231 (2021).</Citation></Reference><Reference><Citation>Bizkarguenaga, M. et al. Uneven metabolic and lipidomic profiles in recovered COVID-19 patients as investigated by plasma NMR metabolomics. NMR Biomed. 35, e4637. 10.1002/nbm.4637 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646702</ArticleId><ArticleId IdType="pubmed">34708437</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia, B. S. B. et al. 1H qNMR-based metabolomics discrimination of COVID-19 severity. J. Proteome Res. 21, 1640–1653 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35674498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liptak, P. et al. Persistence of metabolomic changes in patients during post-COVID phase: a prospective, observational study. Metabolites. 12, 641. 10.3390/metabo12070641 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9321209</ArticleId><ArticleId IdType="pubmed">35888766</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda, R. et al. Integrative modeling of plasma metabolic and lipoprotein biomarkers of SARS-CoV-2 infection in Spanish and Australian COVID-19 patient cohorts. J. Proteome Res. 20, 4139–4152 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34251833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghini, V. et al. Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients. PLoS Pathog. 18, e1010443. 10.1371/journal.ppat.1010443 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022834</ArticleId><ArticleId IdType="pubmed">35446921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente, J. A. et al. Metabolomic diferences between COVID-19 and H1N1 influenza induced ARDS. Crit. Care. 25, 390. 10.1186/s13054-021-03810-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8591432</ArticleId><ArticleId IdType="pubmed">34781986</ArticleId></ArticleIdList></Reference><Reference><Citation>Terruzzi, I. &amp; Senesi Does intestinal dysbiosis contribute to an aberrant inflammatory response to severe acute respiratory syndrome coronavirus 2 in frail patients? Nutrition. 79-80, 110996. 10.1016/j.nut.2020.110996 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462523</ArticleId><ArticleId IdType="pubmed">33002653</ArticleId></ArticleIdList></Reference><Reference><Citation>Israr, M. Z. et al. Association of gut-related metabolites with respiratory symptoms in COVID-19: a proof-of-concept study. Nutrition. 96, 111585. 10.1016/j.nut.2021.111585 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8730784</ArticleId><ArticleId IdType="pubmed">35131599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghini, V. et al. COVID-19: a complex disease with a unique metabolic signature. PLoS Pathog. 19, e1011787. 10.1371/journal.ppat.1011787 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10662774</ArticleId><ArticleId IdType="pubmed">37943960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodge, S. et al. Integrative plasma metabolic and lipidomic modelling of SARS-CoV-2 infection in relation to clinical severity and early mortality prediction. Int. J. Mol. Sci. 24, 11614. 10.3390/ijms241411614 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10380980</ArticleId><ArticleId IdType="pubmed">37511373</ArticleId></ArticleIdList></Reference><Reference><Citation>Danlos, F. X. et al. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell. Death Dis. 12, 258. 10.1038/s41419-021-03540-y (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948172</ArticleId><ArticleId IdType="pubmed">33707411</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, D. et al. The serum metabolome of COVID-19 patients is distinctive and predictive. Metabolism. 118, 154739. 10.1016/j.metabol.2021.154739 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920809</ArticleId><ArticleId IdType="pubmed">33662365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, H. et al. Metabolomic analyses reveal new stage-specific features of COVID-19. Eur. Respir J. 59, 2100284. 10.1183/13993003.00284-2021 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8311281</ArticleId><ArticleId IdType="pubmed">34289974</ArticleId></ArticleIdList></Reference><Reference><Citation>Codo, A. C. et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/Glycolysis-dependent axis. Cell. Metab. 32, 437–446e. 10.1016/j.cmet.2020.07.007 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367032</ArticleId><ArticleId IdType="pubmed">32697943</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Hernández, Y. et al. Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19. Sci. Rep. 11, 14732. 10.1038/s41598-021-94171-y (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8290000</ArticleId><ArticleId IdType="pubmed">34282210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tristán, A. I. et al. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: biomarkers and pathway analysis. NMR Biomed. 36, e4935. 10.1002/nbm.4935 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36945883</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart, D. S. et al. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res. 50, D622-D631. 10.1093/nar/gkab1062 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728138</ArticleId><ArticleId IdType="pubmed">34986597</ArticleId></ArticleIdList></Reference><Reference><Citation>Laíns, I. et al. Urine nuclear magnetic resonance (NMR) metabolomics in age-related macular degeneration. J. Proteome Res. 18, 1278–1288 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838731</ArticleId><ArticleId IdType="pubmed">30672297</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey, D. et al. NMR-based serum metabolomics revealed distinctive metabolic patterns in reactive arthritis compared with rheumatoid arthritis. J. Proteome Res. 18, 130–146 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30376345</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>